Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Medical thoracoscopy (rigid and semirigid) is an effective, safe method for diagnosing and managing pleural diseases. Rigid thoracoscopy demonstrates superior overall diagnostic yield compared to semirigid techniques (flexible forceps/cryobiopsy) due to its ability to obtain larger, deeper biopsies with rigid forceps. However, diagnostic rates become similar when biopsies are successfully obtained.
Limitations of rigid thoracoscopy include restricted maneuverability (especially in posterior/mediastinal areas), increased procedural pain from leveraging against ribs and larger trocars, higher sedation requirements, and a steep learning curve for pulmonologists.
To address these issues, a novel dual-function semirigid thoracoscope (UE FET-680, China) was developed. Its straight working channel accommodates standard rigid biopsy forceps, potentially matching rigid thoracoscopy's diagnostic yield while improving usability. This randomized trial will compare the efficacy and safety of this new device versus conventional rigid thoracoscopy in undiagnosed exudative pleural effusions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dual-function Semi-rigid Thoracoscopy | Experimental |
| |
| Rigid Thoracoscopy | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dual-function semi-rigid thoracoscopy | Device | Patients received pleural biopsy via dual-function semi-rigid thoracoscopy. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic yield | Diagnostic yield is defined as the percentage of participants for whom the allocated thoracoscopic pleural biopsy provides a specific histopathological diagnosis. Malignant pleural disease and other defined histopathological diagnoses will be classified as diagnostic results. Non-specific pleuritis, fibrinous pleuritis, non-interpretable specimens, and cases in which no biopsy is obtained will be classified as non-diagnostic results. | 7 days after the procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Procedural Sedative and Analgesic Requirements | Procedural sedative and analgesic requirements will be assessed by recording the total dose of each sedative or analgesic agent administered during thoracoscopy, including midazolam, pentazocine, and tramadol. The dose of each agent will be recorded separately in milligrams and summarised by treatment group | The day of thoracoscopy. |
| Measure | Description | Time Frame |
|---|---|---|
| Postprocedural Length of Hospital Stay | Postprocedural length of hospital stay is defined as the number of days from the date of thoracoscopy to hospital discharge. | At discharge from the index hospitalization, up to 30 days after thoracoscopy. |
| Direct Medical Costs During the Index Hospitalization |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mingming Deng, MD.,PhD. | Contact | +86 18801336854 | isdeng1017@163.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42419899 | Derived | Xu L, Liu X, Wu H, Xie Z, Wang K, Deng M, Zheng Z, Hou G. Diagnostic yield and safety of Dual-functIon Semi-rigid thoraCoscOpy Versus rigid thoracoscopy for the diagnosis of plEuRal disease (DISCOVER-2): protocol for a randomised controlled trial. BMJ Open. 2026 Jul 8;16(7):e118022. doi: 10.1136/bmjopen-2026-118022. |
Not provided
Not provided
De-identified individual participant data that underlie the results reported in the main publication will be made available upon reasonable request. The shared data will include baseline characteristics, allocated intervention, primary and secondary outcome data, and procedure-related complication data.
Beginning 6 months after publication of the main trial results and ending 5 years after publication.
Researchers who submit a methodologically sound proposal. Access will be subject to approval by the study investigators and execution of a formal data-sharing agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D010996 | Pleural Effusion |
| D010995 | Pleural Diseases |
| ID | Term |
|---|---|
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rigid thoracoscopy | Device | Patients received pleural biopsy via rigid thoracoscopy. |
|
| Disease-specific Diagnostic Sensitivity | Disease-specific diagnostic sensitivity is defined as the percentage of participants with a specific final diagnosis according to the reference standard whose allocated thoracoscopic pleural biopsy provides a specific histopathological diagnosis supporting the same disease. Participants with non-specific biopsy findings who are subsequently diagnosed with malignant pleural disease or tuberculous pleuritis during follow-up will be classified as false-negative biopsy results for the corresponding disease. | Up to 12 months after thoracoscopy. |
| Sampling Quality of Pleural Biopsy Specimens | Sampling quality will be assessed using specimen size, specimen depth, and specimen interpretability. Specimen size will be measured as the largest cross-sectional area of the processed biopsy specimens on microscopic glass slides using ImageJ software and reported in square millimetres. Specimen depth will be assessed according to the presence of thoracic wall fatty tissue. Specimen interpretability will be classified as easily interpretable, interpretable with some difficulty, interpretable with great difficulty, or non-interpretable. | Up to 4 weeks after thoracoscopy. |
| Procedure Duration | Procedure duration will be measured in minutes from skin incision to completion of chest tube placement and wound closure. | The day of thoracoscopy. |
| Operator-assessed Device Performance | Operator-assessed device performance will include image quality, ease of manoeuvring, ease of obtaining a biopsy sample, and the operator's expectation that the biopsy sample will provide a definitive histological diagnosis. Each domain will be assessed immediately after the procedure using a visual analogue scale ranging from 0 to 100, with higher scores indicating better operator-assessed performance. | Immediately after the thoracoscopic procedure |
| Post-thoracoscopy Pain Score | Patient-reported post-thoracoscopy pain will be assessed using a 100-mm visual analogue scale while at rest and while coughing. Scores range from 0 to 100, with higher scores indicating more severe pain. | At 2, 6, 12, 24, and 48 hours after thoracoscopy |
| Procedure-related Complications | Procedure-related complications will be classified as major or minor complications. Major complications include empyema, major haemorrhage defined as a drop in haemoglobin of at least 1 g/dL or requiring blood transfusion, persistent air leak for more than 3 days, and re-expansion pulmonary oedema. Minor complications include subcutaneous emphysema, operative site infection, non-infective fever, and minor haemorrhage. | At discharge from the index hospitalization, up to 30 days after thoracoscopy. |
Direct medical costs during the index hospitalization will be extracted from hospital billing records. These costs include procedure-related costs, anaesthetic and analgesic medication costs, chest tube and drainage-related costs, postprocedural imaging and management costs, and postprocedural hospitalization costs. Costs will be reported in Chinese Yuan. |
| At discharge from the index hospitalization, up to 30 days after thoracoscopy. |